Preclinical Lentivirus Production

CAR-T lentivirus for Preclinical Development

Adoptive transfer of T cells expressing chimeric antigen receptors (CAR-T) is a promising anti-cancer immunotherapeutic strategy. Large quantity of high quality lentivirus is required to genetically engineer large number of a patient's T cells to express CARs, specifically directed towards antigens on tumor cells.

With the cutting-edge lentivirus production platform, Cellomics Technology has been routinely providing Custom Preclinical Grade Lentivirus Production Service for preclinical development of CAR-T immunotherapy. 

Though the lentiviruses are produced for preclinical development,  the same procedure to produce the clinical trial grade lentivirus is followed . Our Custom Preclinical Grade of Lentivirus Production Service meets our customers’ need satisfactorily for preclinical development, providing quick track to translate innovative CAR-T discoveries from laboratory to clinical trial.

Advantages
•  Cost-effective
•  Quick turnaround: 1-2 weeks
•  High titer, high purity, serum-free
•  Fast track for translating your research discovery to clinical trial